OV329 — Topline data
Late 2026
The Company intends to test three doses of OV329, including 5, 7 and 9 milligrams, and anticipates results near year end 2026.Source filing
OVID biotech catalysts & pipeline
OVID THERAPEUTICS INC · Data as of 2026-09-08
Upcoming catalysts
OV4071 — Topline data
in 2027
Data from the study are expected to support initiation of a Phase 2 proof-of-concept study in acute schizophrenia in 2027 and provide insights into future development across additional high-value central nervous system (CNS) indications.Source filing
OV329 — Topline data
mid-2027
Ovid is engaging sites and regulators and intends to initiate a Phase 2a randomized placebo-controlled study evaluating OV329 in adult patients with drug-resistant focal onset seizures planned to initiate in Q2 2026 and complete in mid-2027.Source filing